I am a healthcare professional within Hull
I am a patient within Hull, directed to this site by my healthcare professional
What the scheme has achieved so far...
Short acting beta agonist inhalers (aka 'blue inhalers') are often used to relieve symptoms in asthma. Frequent blue inhaler use can reflect poor asthma control and risk of asthma attacks. The Sentinel Project aims to reduce the number of blue inhalers needed by asthma patients by improving people's asthma control. Blue metered dose inhalers also have a greater impact on the environment than other inhaler types. Improving peoples' asthma control using guideline recommended treatments can also be good for the environment.
This project was initiated in a stepwise fashion across the primary care networks (PCNs) within Hull and East Yorkshire. These figures represent data to September 2021 in 4 primary care networks, where initiation started in November 2020 for PCN 1, February 2021 for PCN 2, June 2021 for PCN 3 and September 2021 for PCN 4.How have these figures been calculated?
The achievements so far have been calculated using publicly available data on short-acting beta agonist (SABA) prescriptions in practices that have participated in the SENTINEL project (openprescribing.com). There is a delay of 2 months for prescribing data to become available. Reduction in SABA prescriptions have been calculated compared with the same month the year before to account for seasonal variation in asthma. Potential carbon savings have been calculated based on estimated 28kg CO2e per SABA MDI inhaler.
10,769 fewer blue inhalers issued for the treatment of asthma
Did you know that frequent use of blue inhalers in asthma can be a sign of poor asthma control and reflect increased risk of an asthma attack?
Equivalent to a saving of 301 metric tonnes CO2e
Did you know that blue metered dose inhalers have a larger carbon footprint compared to other inhalers? Reducing the need for blue inhalers in asthma can be good for the environment as well as being good for patients.